RAYMOND P. MILLER, M.D.; JOSEPH H. BATES, M.D., F.A.C.P.
A follow-up evaluation was done on 53 patients treated with amphotericin B. These data show that an increase in the blood urea nitrogen (BUN) during therapy may not be a valid reason to discontinue this therapy. Advanced age of the patient is a factor that increases the probability for the development of permanent impairment of renal function. The data further indicate that impairment of renal function, both acute and permanent, is not a doserelated phenomenon. Instead, it is an individualized and as yet an unpredictable response. The creatinine clearance during therapy may be reduced by as much as 78% of the pretreatment values and still return to the pretreatment value within 1 to 2 months after the completion of therapy.
MILLER RP, BATES JH. Amphotericin B Toxicity: A Follow-up Report of 53 Patients. Ann Intern Med. ;71:1089–1095. doi: 10.7326/0003-4819-71-6-1089
Download citation file:
Published: Ann Intern Med. 1969;71(6):1089-1095.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use